CIK 0000943819 · Large accelerated filer
RESMED INC
Sign in to watch- Tickers
- RMD RSMDF
- Exchange
- NYSE, OTC
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Jun 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 980152841
- Phone
- 8587462400
- Business address
- 9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA, 92123
Securities
- RMD ResMed Inc. Common Stock NYSE
- RSMDF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,744,605
- in 5 filings, $3.7M under 10b5-1 plans
Net −$3,744,605. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-10-07 | Farrell Michael J. Chief Executive Officer | Option exercise 10b5-1 | +8,009 | $101.64 | $814K | 475,801 |
| 2025-10-07 | Farrell Michael J. Chief Executive Officer | Sale 10b5-1 | −8,009 | $282.85 | $2.3M | 467,792 |
| 2025-10-07 | Farrell Michael J. Chief Executive Officer | Option exercise · ResMed Common Stock Options 10b5-1 | −8,009 | 8,011 | ||
| 2025-10-01 | Sandercock Brett Chief Financial Officer | Option exercise 10b5-1 | +2,000 | $101.64 | $203K | 89,745 |
| 2025-10-01 | Sandercock Brett Chief Financial Officer | Sale 10b5-1 | −3,000 | $274.36 | $823K | 86,745 |
| 2025-10-01 | Sandercock Brett Chief Financial Officer | Option exercise · ResMed Common Stock Options 10b5-1 | −2,000 | 2,000 | ||
| 2025-10-01 | Rider Michael J Global General Counsel | Sale 10b5-1 | −100 | $274.36 | $27K | 11,327 |
| 2025-09-08 | Farrell Michael J. Chief Executive Officer | Option exercise 10b5-1 | +8,009 | $101.64 | $814K | 475,801 |
| 2025-09-08 | Farrell Michael J. Chief Executive Officer | Sale 10b5-1 | −8,009 | $278.14 | $2.2M | 467,792 |
| 2025-09-08 | Farrell Michael J. Chief Executive Officer | Option exercise · ResMed Common Stock Options 10b5-1 | −8,009 | 16,020 | ||
| 2025-09-02 | Mowad-Nassar Nicole Director | Grant or award | +241 | 241 | ||
| 2025-09-02 | Sandercock Brett Chief Financial Officer | Option exercise 10b5-1 | +2,000 | $101.64 | $203K | 90,745 |
| 2025-09-02 | Sandercock Brett Chief Financial Officer | Sale 10b5-1 | −3,000 | $270.77 | $812K | 87,745 |
| 2025-09-02 | Sandercock Brett Chief Financial Officer | Option exercise · ResMed Common Stock Options 10b5-1 | −2,000 | 4,000 | ||
| 2025-08-18 | Hernandez John Director | Option exercise | +2,575 | $148.90 | $383K | 6,620 |
| 2025-08-18 | Hernandez John Director | Sale | −2,575 | $287.10 | $739K | 4,045 |
| 2025-08-18 | Hernandez John Director | Option exercise · ResMed Common Stock Options | −2,575 | 0 | ||
| 2025-08-15 | Rider Michael J Global General Counsel | Grant or award | +2,941 | 11,427 | ||
| 2025-08-15 | Leong Justin Chief Product Officer | Grant or award | +5,462 | 27,180 | ||
| 2025-08-15 | Sandercock Brett Chief Financial Officer | Grant or award | +5,462 | 88,745 |
Page 6 of 18 · 355 trades